TCGA-OR-A5JK-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.547
- INTERFERON_GAMMA_RESPONSE+0.540
- ALLOGRAFT_REJECTION+0.502
- INFLAMMATORY_RESPONSE+0.344
- IL6_JAK_STAT3_SIGNALING+0.334
- COMPLEMENT+0.250
- IL2_STAT5_SIGNALING+0.226
- MYOGENESIS+0.188
- TNFA_SIGNALING_VIA_NFKB+0.187
- KRAS_SIGNALING_UP+0.139
Top 10 suppressed
- PROTEIN_SECRETION-0.447
- MITOTIC_SPINDLE-0.352
- G2M_CHECKPOINT-0.342
- MYC_TARGETS_V1-0.336
- TGF_BETA_SIGNALING-0.324
- E2F_TARGETS-0.318
- HYPOXIA-0.291
- MTORC1_SIGNALING-0.288
- GLYCOLYSIS-0.264
- PEROXISOME-0.254
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_0375_T1_B_RNA | — | D | 0.860 |
| 2 | R117 | — | — | 0.860 |
| 3 | MBCProject_1037_T1_RNA | — | D | 0.839 |
| 4 | TCGA-85-A513-01A-12R-A26W-07 | — | cohortA1 | 0.839 |
| 5 | SRR8942969 | — | — | 0.836 |
| 6 | SRR12202486 | — | — | 0.836 |
| 7 | TCGA-L9-A444-01A-21R-A24H-07 | — | cohortA1 | 0.833 |
| 8 | SRR8518409 | — | D | 0.828 |
| 9 | TCGA-CV-A468-01A-11R-A266-07 | — | — | 0.826 |
| 10 | TCGA-90-A59Q-01A-11R-A26W-07 | — | cohortA1 | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.547 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.540 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.502 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.344 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.334 | Inavolisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.226 | Idelalisib | — uncovered |
| MYOGENESIS | 0.188 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.187 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.139 | Inavolisib | — uncovered |
| COAGULATION | 0.096 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.084 | Inavolisib | — uncovered |
| APOPTOSIS | 0.074 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.069 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.037 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.037 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.037 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.027 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.002 | Idelalisib | — uncovered |